
Mainz Biomed Partners with Microba Life Sciences
Leveraging a platform for measuring the human gut microbiome to discover and develop novel therapeutics for major diseases, Microba and Mainz Biomed...

Tay Therapeutics in licensing deal with VYNE Therapeutics
Tay Therapeutics Ltd’s exclusive license deal with VYNE Therapeutics Inc. on the oral BET inhibitor, TAY-B2 (now known as VYN201) forsees an upfront...

Glioma drug combo turns tumours hot
Swiss researchers have shrinked one of the most lethal and untreatable types of cancer in mice using a combination treatment that proved safe in five...

AI predicts an enzyme’s substrate
Researchers from Germany, Sweden and India have reported an AI method that predicts whether an enzyme can work with a specific substrate. In...

Confo Therapeutics and Lilly partner to advance CFTX-1554
Under the agreement, Confo Therapeutics BV got a $40m upfront and milestone payments totalling $590m for licencing its clinical stage angiotensin II...

Algal enzyme synthesizes gasoline building blocks
Deciphering the mechanism of the photoenzyme Fatty acid photodecarboxylase (FAP), a research team co-headed by Frederic Beisson from University...

Neurodegenerative disorders are being fought with €28m
The Danish biotech Teitur Trophics ApS, aiming to treat chronic neurological disorders, has completed a €28m Series A funding. With the money, Teitur...